Schond L. Greenway, CFO at Avalo Therapeutics, Inc. (AVTX), bought 2,231 shares at $1.57 ($4K) on 2021-12-10, disclosed to the SEC on 2021-12-14.
Open-market purchase of $4k AVTX by CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| MNMD | SELL | 2023-08-28 | $76K | — | Filing → |
| MNMD | SELL | 2023-06-27 | $37K | — | Filing → |
| CERC | BUY | 2021-06-14 | $2K | — | Filing → |